PIK3CA-mutations in breast cancer.

Breast Cancer Res Treat · 2022 · PMC9633529 · PMID 36279023

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In contrast, in SHR-negative larger tumours (≥ 2 cm), patients with PIK3CA- mutations ( n = 14) showed a trend to better 5 years-RFI probability (85.7%) compared to those with wildtype PIK3CA (5 years RFI 66.1%, HR 2.75; 95% CI 0.657–11.527).

also in 53,322 other papers

a strong trendno p-value reported

In SHR-positive BCs with PIK3CA-mutations, a strong trend for impaired RFI was observed (adjusted HR 1.64, 95% CI 0.958–2.807), whilst in SHR-negative BCs PIK3CA -mutations were insignificantly associated with improved RFI (adjusted HR 0.49; 95% CI 0.152–1.597).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.